Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES) : PathIES
| dc.contributor.author | Cheang, M C U | |
| dc.contributor.author | Bliss, J M | |
| dc.contributor.author | Viale, G | |
| dc.contributor.author | Speirs, V | |
| dc.contributor.author | Palmieri, C | |
| dc.contributor.author | Shaaban, A | |
| dc.contributor.author | Lønning, P E | |
| dc.contributor.author | Morden, J | |
| dc.contributor.author | Porta, N | |
| dc.contributor.author | Jassem, J | |
| dc.contributor.author | van De Velde, C J | |
| dc.contributor.author | Rasmussen, B B | |
| dc.contributor.author | Verhoeven, D | |
| dc.contributor.author | Bartlett, J M S | |
| dc.contributor.author | Coombes, R C | |
| dc.contributor.author | PathIES Sub-Committee | |
| dc.date.accessioned | 2018-07-30T14:39:08Z | |
| dc.date.available | 2018-07-30T14:39:08Z | |
| dc.date.issued | 2018-02 | |
| dc.description | This work was supported by Cancer Research UK (C37/A8434) and Pfzer (GA9001DP). Cancer Research UK also providedprogramme grants to the Institute of Cancer Research Clinical Trials and Statistics Unit and the Division of Cancer at Imperial College London. This study was supported by Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre and Imperial Cancer Research UK Centre. MCUC is supported by the Cancer Research UK Core grant (Grant Number C1491/A15955). | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 10 | |
| dc.format.extent | 877955 | |
| dc.identifier | 129546005 | |
| dc.identifier | e749d8cb-6700-4760-ad9d-32dc2101a369 | |
| dc.identifier | 29177605 | |
| dc.identifier | 85035116479 | |
| dc.identifier.citation | Cheang, M C U, Bliss, J M, Viale, G, Speirs, V, Palmieri, C, Shaaban, A, Lønning, P E, Morden, J, Porta, N, Jassem, J, van De Velde, C J, Rasmussen, B B, Verhoeven, D, Bartlett, J M S, Coombes, R C & PathIES Sub-Committee 2018, 'Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES) : PathIES', Breast Cancer Research and Treatment, vol. 168, no. 1, pp. 169-178. https://doi.org/10.1007/s10549-017-4543-7 | en |
| dc.identifier.doi | 10.1007/s10549-017-4543-7 | |
| dc.identifier.iss | 1 | en |
| dc.identifier.issn | 0167-6806 | |
| dc.identifier.other | PubMedCentral: PMC5847042 | |
| dc.identifier.other | ORCID: /0000-0002-0602-4666/work/72631318 | |
| dc.identifier.uri | http://hdl.handle.net/2164/10831 | |
| dc.identifier.vol | 168 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Breast Cancer Research and Treatment | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | Journal Article | en |
| dc.subject | breast cancer | en |
| dc.subject | aromatase | en |
| dc.subject | prognosis | en |
| dc.subject | R Medicine | en |
| dc.subject | Cancer Research UK | en |
| dc.subject | C37/A8434 | en |
| dc.subject | C1491/A15955 | en |
| dc.subject.lcc | R | en |
| dc.title | Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES) : PathIES | en |
| dc.type | Journal article | en |
